Literature DB >> 1706545

Progress in the development of potent bombesin receptor antagonists.

R T Jensen1, D H Coy.   

Abstract

Bombesin and the mammalian-related peptides gastrin-releasing peptide (GRP), GRP and neuromedin B have been shown to have numerous actions in the CNS, gastrointestinal tract and on growth. However, the role of the peptides in various physiological processes has remained unclear because of the lack of potent antagonists. Recent in vitro studies have described four different classes of bombesin receptor antagonist, some of which are active in the nanomolar range and in vivo. Robert Jensen and David Coy describe recent insights into peptide structural determinants of biological activity. Evidence from structure-function studies have resulted in identification of some analogues that function as potent antagonists in all systems examined. Furthermore, various subtypes of bombesin receptors can now be differentiated by these various classes of antagonist.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706545     DOI: 10.1016/0165-6147(91)90483-9

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  28 in total

1.  Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast.

Authors:  M Gugger; J C Reubi
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  Down-regulation of bombesin binding to guinea-pig pancreatic acinar cells during homologous desensitization.

Authors:  L Sjödin; E Gylfe
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

4.  Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

Authors:  A Nagy; P Armatis; R Z Cai; K Szepeshazi; G Halmos; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

Review 5.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

Review 6.  Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

Authors:  Nieves González; Paola Moreno; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2015-06-12       Impact factor: 6.902

7.  The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.

Authors:  Hirotsugu Uehara; Simon J Hocart; Nieves González; Samuel A Mantey; Tomoo Nakagawa; Tatsuro Katsuno; David H Coy; Robert T Jensen
Journal:  Biochem Pharmacol       Date:  2012-07-22       Impact factor: 5.858

8.  Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist.

Authors:  P Hildebrand; F S Lehmann; S Ketterer; A D Christ; T Stingelin; J Beltinger; A H Gibbons; D H Coy; J Calam; F Larsen; C Beglinger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

9.  Bicarbonate and fluid secretion evoked by cholecystokinin, bombesin and acetylcholine in isolated guinea-pig pancreatic ducts.

Authors:  G Szalmay; G Varga; F Kajiyama; X S Yang; T F Lang; R M Case; M C Steward
Journal:  J Physiol       Date:  2001-09-15       Impact factor: 5.182

10.  Depression of primary afferent-evoked responses by GR71251 in the isolated spinal cord of the neonatal rat.

Authors:  J Z Guo; K Yoshioka; M Yanagisawa; R Hosoki; R M Hagan; M Otsuka
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.